--- title: "OrganaBio: The Supply Brain | MSCs" description: MSCs | --- [![OrganaBio-logo-rev-white-copy](https://blog.organabio.com/hs-fs/hubfs/OrganaBio-logo-rev-white-copy.png?width=979&height=239&name=OrganaBio-logo-rev-white-copy.png "OrganaBio-logo-rev-white-copy")](https://www.organabio.com) ![brain](https://blog.organabio.com/hubfs/marketing/brain.png "brain") # The Supply Brain Addressing supply chain challenges in cell and gene therapy. The OrganaBio Blog ## [Simple Science: Cardiac RegenMed](https://blog.organabio.com/en/mscs/simple-science-cardiac-regenmed) Posted by [Jack Camoratto](https://blog.organabio.com/en/author/jcamoratto) on September 01, 2020 - [Tweet](https://twitter.com/share) ## **Simple Science: Cardiac Regenerative Medicine** The field of cardiac regenerative medicine is rapidly developing solutions to treat the millions of people around the world affected by cardiac illnesses. The articles summarized in the Simple Science posts below outline a few of the recent advancements in cardiac tissue engineering, disease modeling, and the role of the stem cell secretome in cardiac protection. OrganaBio’s goal in summarizing these complex articles is to translate regenerative medicine articles that excite our scientists into articles that anyone can enjoy, whether they’re looking for information that inspires hope or just looking for a good read. Scientific articles may be written for a research-savvy audience but, in the end, the discoveries they outline affect us all. We hope you enjoy some Simple Science! [Read More](https://blog.organabio.com/en/mscs/simple-science-cardiac-regenmed) 0 Comments **//** [View or add comments](https://blog.organabio.com/en/mscs/simple-science-cardiac-regenmed#comments-listing) Topics: [Allogeneic Cell Therapy](https://blog.organabio.com/en/tag/allogeneic-cell-therapy), [Exosomes](https://blog.organabio.com/en/tag/exosomes), [MSCs](https://blog.organabio.com/en/tag/mscs), [iPSCs](https://blog.organabio.com/en/tag/ipscs), [Gene Editing](https://blog.organabio.com/en/tag/gene-editing) ## [MSC-Based Therapies for COVID-19](https://blog.organabio.com/en/mscs/msc-based-therapies-for-covid-19) Posted by [Carlos Carballosa](https://blog.organabio.com/en/author/carlos) on August 11, 2020 - [Tweet](https://twitter.com/share) ### **MSC-Based Therapies for COVID-19: Current Clinical Trial Landscape Data** Mesenchymal stem/stromal cells (MSCs) are emerging as a potential treatment modality for COVID-191-3. MSCs have immunomodulatory properties that can be used to combat the inflammatory response caused by the SARS-CoV-2 coronavirus, and the United States Food and Drug Administration (FDA) has granted accelerated approvals to several MSC-based clinical trials for COVID-19. This brief blog post summarizes the current MSC COVID-19 clinical trial landscape based on data from clinicaltrials.gov. [Read More](https://blog.organabio.com/en/mscs/msc-based-therapies-for-covid-19) 0 Comments **//** [View or add comments](https://blog.organabio.com/en/mscs/msc-based-therapies-for-covid-19#comments-listing) Topics: [Allogeneic Cell Therapy](https://blog.organabio.com/en/tag/allogeneic-cell-therapy), [covid-19](https://blog.organabio.com/en/tag/covid-19), [MSCs](https://blog.organabio.com/en/tag/mscs) ## [Cell Therapy for COVID-19](https://blog.organabio.com/en/mscs/cell-therapy-for-covid-19) Posted by [Jordan Greenberg](https://blog.organabio.com/en/author/jordan) on August 03, 2020 - [Tweet](https://twitter.com/share) In late 2019, cases of Coronavirus Disease 2019 (COVID-19) began to emerge out of Wuhan, China. Since then, the disease has proven to be highly contagious and has rapidly spread around the world, becoming a global pandemic. COVID-19 is caused by the Severe Acute Respiratory Distress Syndrome Conoravirus 2 (SARS-CoV-2). SARS-CoV-2 attacks host cells by the binding of its spike protein to the angiotensin I converting enzyme 2 (ACE2) receptor on cell membranes ([1](https://www.ncbi.nlm.nih.gov/pubmed/19198616)). ACE2 receptors are primarily found on lung alveolar type II cells and capillary endothelial cells in the lungs, which helps to explain the prevalence of respiratory distress associated with COVID-19 ([2](https://www.ncbi.nlm.nih.gov/pubmed/32257554)). In addition to the lungs, ACE2 receptors have also been identified in the heart, liver, kidney, and digestive organs which may help to explain why severe COVID-19 patients display myocardial injury, arrhythmia, acute kidney injury, shock, and death from multiple organ dysfunction/failure ([1](https://www.ncbi.nlm.nih.gov/pubmed/19198616)). [Read More](https://blog.organabio.com/en/mscs/cell-therapy-for-covid-19) 0 Comments **//** [View or add comments](https://blog.organabio.com/en/mscs/cell-therapy-for-covid-19#comments-listing) Topics: [Immune Cells](https://blog.organabio.com/en/tag/immune-cells), [Allogeneic Cell Therapy](https://blog.organabio.com/en/tag/allogeneic-cell-therapy), [covid-19](https://blog.organabio.com/en/tag/covid-19), [MSCs](https://blog.organabio.com/en/tag/mscs) ## [You Need Access to a Robust and Reliable Donor Pool](https://blog.organabio.com/en/mscs/de-risking-the-path-to-cell-gene-therapy-commercialization-part-1-you-need-access-to-a-robust-and-reliable-donor-pool) Posted by [Jack Camoratto](https://blog.organabio.com/en/author/jcamoratto) on June 08, 2020 - [Tweet](https://twitter.com/share) ## De-Risking the Path to Cell & Gene Therapy Commercialization Part 1: You Need Access to a Robust and Reliable Donor Pool ![Bridging the Gap from R&D to Clinical Translation](https://blog.organabio.com/hs-fs/hubfs/Imported_Blog_Media/Supply-Chain-1024x768-1.jpg?width=640&height=480&name=Supply-Chain-1024x768-1.jpg) When [cell and gene therapy](https://www.novartis.com/our-focus/cell-and-gene-therapy/what-cell-and-gene-therapy) researchers step into the lab each morning, we envision transforming what may be an early stage experiment into a clinical success. Therapeutics developers spend years working tirelessly to generate pre-clinical data so that, when the time comes, their [Investigational New Drug (IND) application](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4435682/) (or equivalent outside the USA) will be accepted by the appropriate regulatory agency, allowing the therapy to enter clinical trials. However, IND approval is just the first of [many significant hurdles](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4528687/) that therapeutics developers face on the path to commercialization. [Read More](https://blog.organabio.com/en/mscs/de-risking-the-path-to-cell-gene-therapy-commercialization-part-1-you-need-access-to-a-robust-and-reliable-donor-pool) 0 Comments **//** [View or add comments](https://blog.organabio.com/en/mscs/de-risking-the-path-to-cell-gene-therapy-commercialization-part-1-you-need-access-to-a-robust-and-reliable-donor-pool#comments-listing) Topics: [mesenchymal stromal cells](https://blog.organabio.com/en/tag/mesenchymal-stromal-cells), [Immune Cells](https://blog.organabio.com/en/tag/immune-cells), [Allogeneic Cell Therapy](https://blog.organabio.com/en/tag/allogeneic-cell-therapy), [MSCs](https://blog.organabio.com/en/tag/mscs), [Hematopoietic Stem Cells](https://blog.organabio.com/en/tag/hematopoietic-stem-cells), [donor variability](https://blog.organabio.com/en/tag/donor-variability), [Starting Materials](https://blog.organabio.com/en/tag/starting-materials-cell-gene-therapy), [supply chain](https://blog.organabio.com/en/tag/supply-chain), [OrganaBio](https://blog.organabio.com/en/tag/organabio) [All posts](https://blog.organabio.com/en/all) Add a Comment ### Recent Posts ### Posts by Tag - [Allogeneic Cell Therapy (7)](https://blog.organabio.com/en/tag/allogeneic-cell-therapy) - [Immune Cells (4)](https://blog.organabio.com/en/tag/immune-cells) - [MSCs (4)](https://blog.organabio.com/en/tag/mscs) - [OrganaBio (3)](https://blog.organabio.com/en/tag/organabio) - [covid-19 (3)](https://blog.organabio.com/en/tag/covid-19) - [Hematopoietic Stem Cells (2)](https://blog.organabio.com/en/tag/hematopoietic-stem-cells) - [B cells (1)](https://blog.organabio.com/en/tag/b-cells) - [Exosomes (1)](https://blog.organabio.com/en/tag/exosomes) - [Gene Editing (1)](https://blog.organabio.com/en/tag/gene-editing) - [Immunotherapy (1)](https://blog.organabio.com/en/tag/immunotherapy) - [NK cells (1)](https://blog.organabio.com/en/tag/nk-cells) - [Starting Materials (1)](https://blog.organabio.com/en/tag/starting-materials-cell-gene-therapy) - [T cells (1)](https://blog.organabio.com/en/tag/t-cells) - [Uncategorized (1)](https://blog.organabio.com/en/tag/uncategorized) - [cGMP Manufacturing (1)](https://blog.organabio.com/en/tag/cgmp-manufacturing-of-cell-and-gene-therapies) - [donor variability (1)](https://blog.organabio.com/en/tag/donor-variability) - [iPSCs (1)](https://blog.organabio.com/en/tag/ipscs) - [immunomodulation (1)](https://blog.organabio.com/en/tag/immunomodulation) - [mesenchymal stromal cells (1)](https://blog.organabio.com/en/tag/mesenchymal-stromal-cells) - [supply chain (1)](https://blog.organabio.com/en/tag/supply-chain) See all